Warning: getimagesize(): https:// wrapper is disabled in the server configuration by allow_url_fopen=0 in /home/averroeseg/public_html/wp-content/themes/Averroes/single-our_products.php on line 29

Warning: getimagesize(https://www.averroes-eg.com/wp-content/themes/Averroes/upload/Bg-Title.jpg): Failed to open stream: no suitable wrapper could be found in /home/averroeseg/public_html/wp-content/themes/Averroes/single-our_products.php on line 29

Averodab 75 mg

Blood Treatment
Product

Averodab 75 mg

Active

Dabigatran

Category
Blood Treatment
Indication

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery

Dose

The recommended dose of dabigatran is 220 mg once daily . Treatment should be initiated orally within 1–4 hours of completed surgery with a single of 110 mg capsule and continuing with 220 mg once daily thereafter for a total of 10 days.

Patients following elective hip replacement surgery The recommended dose of dabigatran is 220 mg once daily. Treatment should be initiated orally within 1–4 hours of completed surgery with a single dose of 110 mg and continuing with 220 mg once daily thereafter for a total of 28-35 days. For the following groups the recommended daily dose of dabigatran is 150 mg taken once daily as 2 capsules of 75 mg.

Treatment should be initiated orally within 1-4 hours of completed surgery with a single capsule of 75 mg and continuing with 2 capsules once daily thereafter for a total of 10 days (knee replacement surgery) or 28-35 days (hip replacement surgery):

  • Patients with moderate renal impairment (creatinine clearance, CrCL 30-50 mL/min) .
  • Patients who receive concomitant verapamil, amiodarone, quinidine .
  • Patients aged 75 or above for both surgeries, if haemostasis is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery then treatment should be initiated with 2 capsules once daily.